Hypoglycemia News and Research RSS Feed - Hypoglycemia News and Research

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.
Lilly, Adocia team up to develop BioChaperone Lispro insulin for treatment of diabetes

Lilly, Adocia team up to develop BioChaperone Lispro insulin for treatment of diabetes

Eli Lilly and Company and Adocia today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. [More]
Findings show effective treatment for type 1 diabetes patients with severe hypoglycemia

Findings show effective treatment for type 1 diabetes patients with severe hypoglycemia

Type 1 diabetes (T1D) patients who have developed low blood sugar (hypoglycemia) as a complication of insulin treatments over time are able to regain normal internal recognition of the condition after receiving pancreatic islet cell transplantation, according to a new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania, published online in Diabetes. [More]
Opioid tramadol can increase hospitalization risk for hypoglycemia

Opioid tramadol can increase hospitalization risk for hypoglycemia

The opioid pain-reliever tramadol appears to be associated with an increased risk of hospitalization for hypoglycemia, a potentially fatal condition caused by low blood sugar, according to a report published online by JAMA Internal Medicine. [More]
External artificial pancreas improves glucose control, reduces hypoglycemia risk

External artificial pancreas improves glucose control, reduces hypoglycemia risk

The world's first clinical trial comparing three alternative treatments for type 1 diabetes was conducted in Montréal by researchers at the IRCM and the University of Montreal, led by endocrinologist Dr. Rémi Rabasa-Lhoret. [More]
New findings could help develop therapeutic options for glycogen storage disease

New findings could help develop therapeutic options for glycogen storage disease

Glycogen storage disorders, which affect the body's ability to process sugar and store energy, are rare metabolic conditions that frequently manifest in the first years of life. Often accompanied by liver and muscle disease, this inability to process and store glucose can have many different causes, and can be difficult to diagnose. [More]
Promising results for low-dose insulin in paediatric diabetic ketoacidosis

Promising results for low-dose insulin in paediatric diabetic ketoacidosis

Results of a randomised trial suggest that low-dose insulin may be at least as good as standard-dose insulin for the treatment of children with diabetic ketoacidosis. [More]
Economic impact of hypoglycaemia: an interview with Dr Klaus Henning Jensen

Economic impact of hypoglycaemia: an interview with Dr Klaus Henning Jensen

Hypoglycaemia is the term used to describe a lower than normal blood sugar level. There are a number of things that actually need to be formally defined in order for a hypoglycaemic episode to be diagnosed. [More]
Managing diabetes and intensive exercise: an interview with Dr Rafael Castol, Team Novo Nordisk

Managing diabetes and intensive exercise: an interview with Dr Rafael Castol, Team Novo Nordisk

Team Novo Nordisk is a professional cycling team that races at UCI Pro Continental level. It's the first ever team to be made up of athletes diagnosed with Type 1 diabetes. The team was created three years ago, and is part of the Changing Diabetes initiative developed by Novo Nordisk. [More]
First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

MSD, known as Merck & Co., Inc. (NYSE: MRK) in the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development programme for omarigliptin, MSD’s investigational treatment for type 2 diabetes. [More]
FDA approves Contrave extended-release tablets for chronic weight management

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. [More]
Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

Fractyl Laboratories Inc. today announced positive clinical data for the first procedural therapy to directly treat the underlying digestive causes of insulin resistance in patients with uncontrolled type 2 diabetes. [More]
Researchers discover protein that may open door to new method of treating type 2 diabetes

Researchers discover protein that may open door to new method of treating type 2 diabetes

The STK25 protein contributes to cell growth. Researchers at Sahlgrenska Academy have discovered that the protein also affects metabolism, demonstrating that elevated levels accelerate the progress of diabetes in mice. [More]
Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite Aid, Kroger and many other leading chain and independent retailers, according to Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. [More]
Lilly and Boehringer Ingelheim's Basaglar (insulin glargine injection) gets FDA's tentative approval

Lilly and Boehringer Ingelheim's Basaglar (insulin glargine injection) gets FDA's tentative approval

The U.S. Food and Drug Administration today granted tentative approval for Basaglar (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes. [More]
Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. [More]
GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S. [More]
Single injection of protein FGF1 enough to restore blood sugar levels

Single injection of protein FGF1 enough to restore blood sugar levels

In mice with diet-induced diabetes—the equivalent of type 2 diabetes in humans—a single injection of the protein FGF1 is enough to restore blood sugar levels to a healthy range for more than two days. [More]
Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal. [More]
Animas' predictive algorithm technology maintains glucose above hypoglycemic levels

Animas' predictive algorithm technology maintains glucose above hypoglycemic levels

Animas Corporation today shared encouraging results from its predictive hypoglycemia-minimizing algorithm in development. [More]
Bionic pancreas device controls blood sugar in patients with type 1 diabetes

Bionic pancreas device controls blood sugar in patients with type 1 diabetes

The latest version of a bionic pancreas device has been successfully tested in two five-day clinical trials - one in adults, the other in adolescents - that imposed minimal restrictions on patient activities. [More]